Page 7 of Attachment B 
The mayor of Indianapolis, a vice president of Indiana University (who 
is a physician), and a pathologist from Indiana University Medical 
School (an expert on infectious disease) are the non-company members 
of the IBC. The I BC reviews the work of the protocol review subcommittee 
(of the corporate safety and health committee) which is responsible for 
making containment recommendations for all recombinant DNA protocols, 
laboratories, production areas and procedures. 
Work practice guidelines are maintained and available for specific pro- 
cedures requiring personal protective equipment or precautions. Specia- 
lized safety equipment, laboratory coats, shoes, and glasses are provided 
by the company. Specific training programs for employees involved with 
recombinant DNA procedures have been instituted to instruct them in 
good work practices, process requirements, and emergency procedures. 
These include audio-visual presentations and instruction by supervisors. 
Communication meetings are held to discuss the status of recombinant DNA 
technology, the NIH Guidelines, and Lilly's advances in the field. 
Industrial Hygiene 
Environmental monitoring is limited to RODAC (Replicate Organism Direct 
Agar Contact) plates, air impaction onto agar plates, settling plates 
filled with agar, and liquid impinger techniques. Monitoring is per- 
formed on a scheduled basis during each run, and records are maintained. 
No viable recombinant organisms have been recovered. However, the 
sensitivity and accuracy of sampling and analytical techniques have 
not been documented for various culture and environmental conditions 
which may be encountered; the ability to recover viable culture organisms 
from contaminated surfaces or air has not been determined. 
Medical Program 
The company's medical department is staffed by a director of industrial 
medicine, five full-time physicians, and eight nurses who serve the 
employees in the Indianapolis area. Pre-employment physicals are given 
to newly hired employees. Comprehensive annual physicals are given to 
all employees and annual physical examinations are mandatory for all 
laboratory and production personnel (including recombinant DNA workers) . 
Company policy states that all injuries must be reported to the plant 
physician and any employee on sick leave for more than five days must 
report to the physician before returning to work. Employees undergoing 
antibiotic therapy are excluded from working in recombinant DNA areas. 
Employees involved with recombinant DNA processes who develop chronic 
or acute illness are required to see the physician. Preassignment 
blood serum samples are maintained for individuals working with recom- 
binant DNA processes. When appropriate, immunizations are given to 
those employees working with infectious organisms. 
4 
[ 507 ] 
